An excel file with datasets of differentially expressed protein, mRNA , and microRNA, as well as a dataset of the proteins detected in all TMT sets.
adult patient within 1 year after administration of the drug and is commonly associated with a dilated and hypokinetic cardiomyopathy leading to heart failure (Cardinale et al., 2015) . The excessive production of reactive oxygen species (ROS) upon administration has been well known since the anthracyclines started to be used clinically, and has together with alterations in iron metabolism been the most accepted mechanistic explanation for the cardiotoxicity (Ghigo et al., 2016) . However, the ROS formation and iron metabolism can only partly explain the cardiotoxicity of doxorubicin. Few iron chelators show a satisfactory effect on the ROS formation and altered iron metabolism ( Simůnek et al., 2009) , and only the use of dexrazoxane has been approved as an cardioprotective strategy during chemotherapy (Ghigo et al., 2016) . Other mechanistic explanations for anthracycline-induced cardiotoxicity include modulation of signaling networks involving DNA damage responses, cardiomyocyte survival, cardiac inflammation, energetic stress, and gene expression modulation (Ghigo et al., 2016) .
Human pluripotent stem cells with their ability of unlimited propagation and differentiation capacity offer a very attractive source of specialized cells for in vitro models (Takahashi et al., 2007; Thomson et al., 1998) . The utility of cardiomyocytes derived from human pluripotent stem cells to study anthracycline-induced cardiotoxicity has previously been demonstrated in several studies, focusing on transcriptional changes upon doxorubicin exposure (Chaudhari et al., 2016a,b; Holmgren et al., 2016 Holmgren et al., , 2015 as well as on more mechanistic investigation of cardiotoxic events (Eldridge et al., 2014) , including the use of patient specific human pluripotent stem cell-derived cardiomyocytes from individuals with various sensitivity to doxorubicin-induced cardiotoxicity (Burridge et al., 2016) . However, the global protein expression changes related to doxorubicin-induced cardiotoxicity remain elusive.
Advances in mass spectrometry-based proteomics now enable the measurement of multiple characteristics of proteins, such as their abundance and subcellular localization, on a global scale, closing in on what is possible to do at the genetic level. Stable-isotope labeling of proteins in vitro, using covalently bound chemical tags, such as dimethyl-labelling (Boersema et al., 2009; Hsu et al., 2003) , tandem mass tags (TMTs) (Thompson et al., 2003) and isobaric tags for relative and absolute quantification (Ross et al., 2004) , allows for the relative quantification of many proteins in biological samples simultaneously. Improvements in the analysis of the proteome have also contributed to a better understanding of advanced cellular and physiological processes.
The development of various high-throughput omics techniques, such as microarrays, next generation sequencing, and quantitative mass spectrometry allow the generation of large quantities of data from multiple levels of complexity, commonly referred to as biomedical big data (BBD) (Margolis et al., 2014) . In addition to large datasets, BBD also refers to the complexity, challenges, and new opportunities presented by the combined analysis of these data (Margolis et al., 2014) . To fully make use of these vast datasets, new methods and procedures to integrate and visualize different types of data are needed in order to facilitate explorative analytics and the interpretation of multi-omics data at a systemic level. In the present study, we investigated doxorubicin-induced cardiotoxicity in human pluripotent stem cell-derived cardiomyocytes using proteomics. In addition, different sources of omics data (protein, mRNA, and microRNA) from the same experimental setup were further combined and analyzed. Interesting differential expression patterns that show a linkage between the proteome, transcriptome, and the regulatory microRNA network, were identified. These findings help to increase the understanding of the mechanisms behind and suggest putative biomarkers for anthracyclineinduced cardiotoxicity.
MATERIALS AND METHODS
Cell culture. Human pluripotent stem cell-derived cardiomyocytes, Cellartis Pure hES-CM, were obtained from Takara Bio Europe AB (Gothenburg, Sweden) and cultured under serum free conditions according to the Cellartis Cardiomyocyte User Manual (Cat. No. Y10075, Clontech). The cells were thawed and seeded (200 000 viable cells/cm 2 ) in 12 well culture dishes. After a recovery period of 6 days post thawing, with medium changes every second day, the cells were incubated with, or without doxorubicin (D1515, Sigma-Aldrich, Sweden) at various concentrations (50, 150, or 450 nM) for up to 2 days. A concentration of 450 nM correlates well to the peak plasma concentrations seen during clinical use of doxorubicin (Barpe et al., 2010; Hempel et al., 2002) . The 2 additional concentrations of doxorubicin (50 and 150 nM), were included in order to study dose-dependent effects. The drug exposure was followed by a 12 days wash-out period. The experiments were performed in triplicate.
Cell harvest. At selected time points during the study (days 0, 1, 2, 7, and 14 from the start of compound exposure), cells were harvested for subsequent RNA and protein isolation. Total RNA and protein were extracted using GenElute RNA/DNA/Protein Plus Purification Kit (E5163, Sigma-Aldrich, Sweden). Quantification of nucleic acids and total protein content was performed on a NanoDrop ND-1000 (Nanodrop, Thermo Fisher Scientific).
RNA and microRNA profiling. The generation of large-scale mRNA-and microRNA expression profiling datasets from these experiments have been described elsewhere (Holmgren et al., 2015 (Holmgren et al., , 2016 and are publicly available at ArrayExpress (Accession number: E-MTAB-6045 and E-MTAB-6052). These datasets have been re-analyzed using methods described in "Data analysis and identification of differential expression\ section.
Protein digestion and TMTs labeling. For each TMT 10-plex set, 30 mg of total protein of each sample and 30 mg of a reference pool containing aliquots of samples from all groups were transferred to tubes for protein reduction, alkylation and digestion. The samples were trypsin digested using the filter-aided sample preparation method modified from (Wisniewski et al., 2009) . In short, reduced samples were applied on Nanosep 30k Omega filters (Pall Life Sciences) and 8 M urea were used to repeatedly wash away the SDS. Alkylation was performed and proteins doubly trypsin digested in buffer (1% sodium deoxycholate [SDC] , 50 mM triethylammonium bicarbonate [TEAB] ), and the filters were repeatedly washed with digestion buffer. The peptides were collected by centrifugation and subjected to isobaric mass tagging reagent TMT according to the manufacturer's instructions (Thermo Fisher Scientific). The combined samples in a set were acidified to precipitate SDC. The peptides were further purified using Pierce C18 Spin Columns (Thermo Fisher Scientific) according to the manufacturer's guidelines.
LC-MS/MS analysis.
The 10-plexed TMT-labeled sample was analyzed on an Orbitrap Fusion Tribrid mass spectrometer interfaced to an Easy-nLC II (Thermo Fisher Scientific). Peptides were separated using an in-house constructed analytical column packed with 3 lm Reprosil-Pur C18-AQ particles (Dr Maisch, Germany). The increasing acetonitrile gradient was run during 90 min in 0.2% formic acid and ions electrosprayed in positive mode. MS scans were performed in the Orbitrap over m/z range 400-1200, MS/MS analysis was performed in a data-dependent mode by collision-induced dissociation at 30% with detection in the ion trap, for both the most and least intense doubly or multiply charged precursor ions. Multi-notch (simultaneous) isolation of the top 10 MS2 fragment ions, with m/z 400-900, selected for fragmentation (MS3) by high energy collision dissociation (HCD) at 55% and detection in the Orbitrap at 60 000 resolution, m/z range 100-500, was performed for relative quantification. After these 4 injections per TMT set, the raw files were matched for peptide identity and exclusion lists of peptide masses were prepared to be used in additional 2 injections per sample set.
Database search for protein relative quantification. Three MS raw data files for each TMT set were merged for relative quantification and identification using Proteome Discoverer version 1.4 (Thermo Fisher Scientific) with the Mascot search engine (Matrix Science). The Homo sapiens Swissprot Database version April 2015, MS peptide tolerance of 5 ppm and MS/MS tolerance of 500 millimass units was used for identification. Tryptic peptides were accepted with zero missed cleavage and variable modifications of methionine oxidation and fixed modifications of cysteine alkylation, Nterminal TMT-label and lysine TMT-label were selected. The ratios of the TMT reporter ion intensities in HCD MS/MS spectra (m/ z 126-131) from raw data sets were used for relative quantification. Only peptides unique for a given protein were considered for relative quantitation, excluding those common to other isoforms or proteins of the same family. The quantification was normalized using the protein median. The detected peptide threshold in the software was set to 1% false discovery rate (FDR) by searching against a reversed database and identified proteins were grouped by sharing the same sequences to minimize redundancy. The complete dataset of proteins identified in all TMT sets is available from the Dryad Digital Repository: https://doi.org/10.5061/dryad. g335f; last accessed January 31, 2018.
Data analysis and identification of differential expression. To facilitate integration and comparison of results from the different omics datasets, the f-divergence cutoff index (fCI) model (Tang et al., 2016) was chosen for identification of differentially expressed (DE) proteins, mRNAs and microRNAs using the R statistical software (version 3.2.5) package fCI. The fCI model can be applied to various types of data, such as microarray data and isobaric-labeled LC/MS-MS expression measurements. Briefly, the fCI creates control-control and control-treatment combinations and compares the similarity of the ratio distributions for of the different combinations. If the treatment causes upregulation or downregulation of expression, differences in the distribution of the ratios from control-treatment pairs compared with the control-control (empirical null) distribution will appear. To identify DE molecules (ie, genes or proteins) the difference between the distributions is quantified by the f-divergence. The Hellinger distance is used to calculate the fdivergence and molecules are removed from both tails of the control-treatment distribution until the remaining distribution is similar or identical to the empirical null distribution. The removed items are classified as dysregulated and the analysis output contains a list of the dysregulated molecules for all the pairwise analysis results including the total number of times an item is found to be dysregulated and the coverage percentage.
In this study, proteins and genes that are dysregulated in all 3 replicates are considered DE. The fCl method was applied on each of the available global omics datasets representing proteins, mRNAs and microRNAs, and lists of DE molecules from each dataset were compiled.
To investigate the effect of treatment versus time on the protein expression a principal component analysis (PCA) was performed using the prcomp function in R with zero-centered data scaled to unit variance.
The K-means clustering of the DE proteins was performed using Cluster 3.0 software with Pearson correlation as the distance method and the number of cluster set to 5 (de Hoon et al., 2004; Eisen et al., 1998) . The result was visualized using the Java TreeView software (Saldanha, 2004) .
Overrepresentation analysis and integrated visualization. To identify over-represented pathways and gene ontology (GO) terms amongst the DE proteins and mRNAs, the meta-database ConsensusPathDB (http://cpdb.molgen.mpg.de/; last accessed January 31, 2018), which integrates the content of currently 32 public resources for interactions, was used. A p-value cut-off of .01 was chosen as analysis parameter for the GO term analysis, with an additional criterion of a minimum overlap of 2 proteins between the pathways and the input lists for the pathway analysis.
The Integrated analysis of Cross-platform MicroArray and Pathway data (InCroMAP) application (Wrzodek et al., 2012 (Wrzodek et al., , 2013 was used to visualize the expression of the DE proteins, mRNAs, and microRNAs. The lists of DE proteins, mRNA, and microRNA were used as input to the application and "Integrated heterogeneous data visualization" for relevant KEGG pathways was performed.
RESULTS

Cellular Effects of Doxorubicin
Four days after thawing and plating, the cells had formed a confluent layer of spontaneously contracting cells. At day 6 post-thawing, the cells were exposed to doxorubicin in different concentrations (50, 150, and 450 nM). As we previously reported (Holmgren et al., 2015 (Holmgren et al., , 2016 , the cardiomyocytes displayed a clear morphological change, most prominently observed in the 450-nM treated group, upon doxorubicin exposure. The treated cells also exhibited a reduced contractility. The effect of doxorubicin was sustained throughout the 14 days experimental period, with more spare cells and altered contractility in the treated groups. As reported previously in Holmgren et al. (2016) , the total protein content isolated from each group also suggest that some degree of general cell death or inhibited cell proliferation occur in the doxorubicin treated groups.
Protein Expression Profiling
Identification and relative quantification of proteins from the total protein isolates were performed using 10-plex TMT-labeled LC-MS/MS as described in the method section. The complete dataset (Data available from the Dryad Digital Repository: https://doi.org/ 10.5061/dryad.g335f; last accessed January 31, 2018) of proteins detected in all the different TMT sets were subject for quality assessment showing that the expression distribution for all samples demonstrate an even distribution of detected proteins, which rationalizes a global analysis of all proteome samples.
PCA of the mean ratio values from all 3 replicates was performed and the results demonstrate a relevant separation of the samples. Figure 1 depicts the first 2 components from the PCA, which contributes to >50% of the variation (PC1 ¼ 42.3% and PC2 ¼ 13.7%). A clear separation of the samples by the time factor can be observed as samples from each time point (indicated by color) cluster together and drift towards the lower right corner in the plot (indicated by the arrow). Within each cluster for the days 2, 7, and 14 samples, a separation of the treatment (shapes of nodes) is apparent and samples from the different doses separate along the indicated arrow towards the upper right corner.
Differential Expression of Proteins
In order to identify DE proteins in the samples, the f-divergence cut off index model (Tang et al., 2016) was applied to the protein dataset. The method was applied to each replicate of the treated samples separately and proteins detected as DE in all 3 replicates were considered significant and selected for further analysis. As shown in Figure 2A , a clear dose dependent increase in the number of DE proteins is evident at each time point. Except from at day 7, a majority of the DE proteins are downregulated. When looking at the profiles over time, the low (50 nM) and the middle (150 nM) concentration of doxorubicin result in an increase of the DE proteins during days 1, 2, and 7 while at day 14 the number of DE proteins has declined. In the 450 nM samples, the number of DE proteins continues to increase also at day 14 compared with previous days and this might indicate that the cells, at the lower concentrations of doxorubicin, are to some extent able to recover from the doxorubicin treatment. In total, the fCI analysis identifies 199 unique proteins that show differential expression in at least one treatment group compared with the controls during at least one time point. The number of DE proteins represents 27% of the total number of 724 proteins detected in all of the TMT sets.
As expected and illustrated in the Venn diagram in Figure 2B , the majority of the DE proteins at each time point are present in the 450-nM treatment group (ie, 21 out of 22 at day 1, 65 out of 81 at day 2, 80 out of 101 at day 7, and 93 out of 100 at day 14). Furthermore, when analyzed for pathway overrepresentation, the 41 DE proteins that are present in the lower concentrations (50 and 150 nM) but not in the 450 nM treatment, were found to be related to cardiomyocytes (data not shown). Thus, we used the union of all DE proteins at each time point for the succeeding analysis.
Amongst the identified DE proteins we observed cardiomyocyte-related proteins such as the myosin light chain family (MYL2, MYL3, MYL4, MYL6, MYL7, and MYL12A), myosin heavy chain (MYH7, MYH9, and MYH10), troponins (TNNC1, TNNI3, and TNNT2), and tropomyosin (TPM1, TPM2, and TPM4); ribosomal proteins from the RPL family; mitochondrial associated protein such as the COX family, MT-CO2, NDUF family, ATP family, and UQCR10; and proteins linked to ROS formation such as TP53I3.
Pathway Overrepresentation Analysis
Pathway over-representation analysis of the DE proteins at each time points revealed a clear effect on cardiomyocyte related signaling pathways (Table 1 ). The following 4 over-represented pathways are present at all time points: Cardiac muscle contraction-H. sapiens (human) (KEGG entry: hsa04260); Hypertrophic cardiomyopathy (HCM)-H. sapiens (human) (KEGG entry: hsa05410); Dilated cardiomyopathy-H. sapiens (human) (KEGG entry: 05414); Ribosome-H. sapiens (human) (KEGG entry: hsa03010).
Clusters of DE Proteins
To further investigate the expression profiles of the identified DE proteins, all treated groups were compared with the control at each time point, and a heat map of the fold change values is shown in Figure 3 . K-means clustering, with Pearson correlation as distance measurement, demonstrate a separation into 5 distinct clusters with different expression profiles. The different clusters were analyzed for over-represented GO terms, and a table of all over-represented GO terms is provided as Supplementary Material. Cluster 1 that shows an early upregulation upon doxorubicin exposure has an over-representation of GO term related to general regulation of cell communication, cell signaling, and protein localization together with an activation of mitochondrial apoptotic signaling. Cluster 2 and 4 contain proteins that are downregulated upon doxorubicin exposure and are clearly connected to muscle contraction and the functionality of the cardiomyocytes. These clusters also show an over-representation for GO terms connected to ribosomes, protein localization, protein folding, and protein complex assembly/disassembly. Furthermore, cluster 3 shows an even more pronounced connection to cardiomyocyte function and contractility but in contrast to clusters 2 and 4 mainly shows protein upregulation, especially at day 7. The last cluster consists of proteins that are upregulated by doxorubicin and shows an elevated upregulation over time. Besides the connection to muscle cell contraction, proteins related to different metabolic and biosynthetic processes are over-represented in this cluster.
Integration of Multiple Omics Data
The over-representation analysis of the DE proteins clearly shows that cardiomyocyte-related signaling pathways and cardiomyocyte function is affected by the doxorubicin treatment.
To further investigate how doxorubicin influences the cardiomyocyte functionality, previously generated transcriptomics data (Holmgren et al., 2015 (Holmgren et al., , 2016 , both mRNA-and microRNA global expression datasets, were reanalyzed and the results were integrated with the findings from the proteomics data. Similarly, as for the proteomics dataset, the fCI method was applied also to the transcriptomics datasets and 7437 mRNAs and 387 microRNAs were identified that show differential expression in at least one treatment group during at least 1 time point. In total 83 out of the 199 DE proteins overlap with the DE mRNAs. To investigate and visually integrate the omics data from the different molecular levels, the KEGG pathways that were over-represented among the DE proteins at all time points, were selected for additional analysis. Since most of the DE proteins and genes were identified in the 450 nM treatment group, this group was chosen for the subsequent visualization.
InCroMAP analysis tool enables for integrated visualization of the DE proteins, mRNAs, and microRNAs in a combined view. Figure 4 displays the connection to cardiac muscle contraction during the different time points of the study. This analysis revealed a clear downregulation of genes and proteins connected to the myofibrils in the cardiomyocytes, such as myosin light and heavy chain (MYLs and MYHs), tropomyosins (TPMs) actin (ACTC1), and troponins (TNNTs), during the acute toxic phase at day 1 and 2 ( Figs. 4A and 4B ). The expression levels of these are shifted towards an upregulation during the wash-out period, most prominently seen at the protein level (Figs. 4C and 4D) . In connection to the dysregulated contractile function, there is also a clear effect of doxorubicin on important ion channels, with a downregulation of CACNs, SCL8A1, and FXYD2, and an upregulation of SLC9A1 (Figs. 4A and 4B ). This altered mRNA expression of ion channels is observed during the exposure period and is later returned to control levels during the washout period. In addition, there is an increasing upregulation over time of genes and proteins related to the mitochondrial function, such as COXs, and UQCRs. The 2 disease-related KEGG pathways: HCM and dilated cardiomyopathy (Figs. 5 and 6 ), are to a large extent overlapping in terms of genes and proteins involved. Obviously, the contribution of myofibrillar function and ion channels described earlier has an important role also for these pathways, but in addition these pathways also include interactions with extracellular matrix receptors, such as integrins, ACT, and glycan complexes; the renin-angiotensin pathway; JAK-STAT signaling pathway; and TGF-beta signaling pathway. For the later pathways it is mainly the TGFB gene and microRNAs targeting these genes that show differential expression. Exclusively for the HCM pathway ( Figure 5 ) is the involvement of AMP-activated protein kinase (AMPK), an energy-sensing enzyme important for monitoring of cellular energy status. Several of the mRNAs coding for subunits of AMPK are DE in this study. Some of the mRNAs are initially downregulated at day 1 but shift to an upregulation over time, while others, eg, PRKAB1 and PRKAB2, show a strong upregulation early that fades over time. Noteworthy, several related microRNAs, especially miR-301b, miR-335-5p, and the miR-320 family, show an inverted correlation to their mRNA targets. The patterns seen on mRNA level is also reflected at the protein level with an upregulation of PRKAG1 and PRKAR1A. In connection to the AMPK activation, the dilated cardiomyopathy pathway contains an involvement of adenylate cyclases and GNAS complex locus. Both of these are players in the formation of the signaling molecule cAMP and show an upregulation during the acute toxic exposure (days 1 and 2). GNAS shows an early upregulation during toxic exposure, followed by a downregulation during the wash-out period also at the protein level. In addition several associated microRNAs, such as miR-301b, and miR-335-5p are downregulated over time.
The ribosome pathway visualization ( Figure 7) indicates a strong dysregulation of certain ribosomal proteins and mitochondrial ribosomal proteins, especially during the acute toxic phase. For instance, PRS27 and MRPL33 showed a high upregulation at days 1 and 2 which diminishes during the wash-out period. Other genes, like MRPL12 and RPL22, showed a downregulation in a similar manner. Additional genes, like MRPL15 and MRPL24, showed a downregulation during exposure that shifts towards upregulation during the wash-out period. A majority of the DE proteins present in the pathway showed a downregulation at all time points. Noteworthy, the DE microRNAs present in the pathway image do not correlate to DE mRNA targets.
DISCUSSION
Cardiotoxicity induced by anthracyclines, such as doxorubicin, is hampering the usefulness of these compounds as chemotherapeutic agents. Despite intense research, a complete understanding of the molecular mechanisms triggering this cardiotoxicity has not yet been fully elucidated.
In this study, we used human pluripotent stem cell-derived cardiomyocytes to assess the effect of doxorubicin exposure on the global protein expression. We also integrated the findings at the proteomic level to transcriptomics data of mRNAs and microRNAs, in order to create an in-depth understanding of the mechanisms behind the anthracycline-induced cardiotoxicity, as well as to identify biomarker candidates that may be useful as indicators of this condition. Secreted and circulating microRNAs and proteins which could be readily assessed in blood samples represent possible biomarker for doxorubicininduced cardiotoxicity. However, the selectivity and specificity of such biomarkers must be established and clearly linked to the incidence and severity of the toxic insult.
The cardiomyocytes form a confluent layer of cells and show a functional contractility shortly after thawing and plating. As reported previously (Holmgren et al., 2015 (Holmgren et al., , 2016 , the 2-day doxorubicin exposure, at concentrations known to affect the cells without causing substantial cytotoxicity, alters the morphology and the functionality of the cells. These effects were sustained throughout the 12-day wash-out period. The doxorubicin treatment causes a clear effect on the expression of proteins in the cells, with a dose-dependent increase of the number of DE proteins. In order to minimize the risk for any bias simply related to the in vitro culture of the cell over the treatment period, parallel cultures of cells were maintained without doxorubicin treatment and used as reference samples during the analysis.
Upon the doxorubicin treatment, there is an early triggering of apoptotic signaling pathways, with upregulation of proteins like TP53I3 and BAG3, in the cells, indicating an acute response to the toxic exposure. This correlates well with the morphological appearance of the cell cultures with more spares cells in the doxorubicin treated groups, and to the measurement of the total protein content reported before (Holmgren et al., 2016) which suggest either some degree of general cell death or proliferation inhibition.
The protein data demonstrate a dysregulation of AMPKs, with a downregulation of PRKAG1, PRKAR1A, and PRKAR2A at day 1 and a subsequent upregulation during the remaining time points. These data are in line with the early apoptotic signaling, since AMPKs are critically involved in p53-dependent DNA damage and apoptosis (Wang et al., 2012) .
AMPKs also work as a central sensor and regulator of energy and nutrient signaling and the surviving cells show a shift in the expression of proteins related to energy metabolism, something that is in accord with recent reports of metabolic shift in cardiomyocytes during heart failure (Bedi et al., 2016; Kolwicz et al., 2016) . The K-means clustering depicted in Figure 3 demonstrates that the DE proteins show different expression profiles. Cluster 5 contains proteins that are elevated during doxorubicin exposure and increasingly overexpressed throughout the experiment. The over-representation analysis links these proteins to various metabolic processes indicating an altered metabolism in the treated cells. Vijay et al. recently reported a study on early genetic responses to doxorubicin in mice (Vijay et al., 2016) . Out of the list of 268 mitochondria-related genes investigated in that study, 18 were identified as DE proteins in our data. Noteworthy, 17 of these can be found in cluster 5 and are connected to oxidative phosphorylation, fatty acid metabolism, and Krebs cycle, according to their associated GO terms.
Furthermore, the doxorubicin exposure increases expression of ACO2 of the iron regulatory protein (IRP) family, involved in the regulation of free iron within the cell. It has been reported that doxorubicin inactivates IRPs, leading to events that increase free intracellular iron and cause cellular damage (Minotti et al., 2001) .
In general, it seems that doxorubicin causes an altered expression of key proteins for the cardiomyocytes contractile function and energy production. Effects are seen on the abundance of proteins that constitute the myofibrils, such as MYLs, MYHs, TPMs, and troponins, as well as proteins involved in the mitochondrial function, like the COX family, MT-CO2, NDUF family, ATP family, and UQCR10. Ghigo et al. (2016) recently reviewed the current status of studies investigating the complex network of mechanisms involved in doxorubicin-induced cardiotoxicity. Our study demonstrates an effect of doxorubicin exposure on many of the key players at the mRNA level. For instance, our data show dysregulation of genes encoding ferritin (FTHL17), transferrin receptor, hemochromatosis type 2, and ABCB6, all involved in iron regulation. Furthermore, we see an effect on the mRNA levels of the main targets for doxorubicin, topoisomerases TOP2A and TOP2B (Data available from the Dryad Digital Repository: https://doi. org/10.5061/dryad.g335f; last accessed January 31, 2018), genes involved in nitric oxide synthase signaling (NOX1), the Neuregulin/ErbB survival signaling (NRG1, ERBB2, ERBB3, and ERBB4), as well as on b-adrenergic receptors like ADRB2. Interestingly, a recent report demonstrated that disruption of the TOP2B gene significantly reduced the sensitivity of human pluripotent stem cell-derived cardiomyocytes to doxorubicininduced cell death (Maillet et al., 2016) . Despite the clear effects at the mRNA level, none of these key genes are DE at the protein level in our data. One possible explanation for the observed discrepancy between the transcriptomics and proteomics data can be the fact that much of the effects by doxorubicin involves activation and inactivation of proteins, phosphorylation, accessibility to binding sites, disruption of protein complexes, and inhibition of protein functions etc. effects that might not be picked up when analyzing the abundance of proteins and identification of differential expression. These types of studies which unravel dependencies between different molecular levels require integrated analysis approaches where multiple omics data sets are analyzed together at a more systemic level (Gligorijevic et al., 2016; Lin and Lane, 2017; Nishimura and Hara, 2016) .
Besides the clear effects on the contractile apparatus and the mitochondrial dysregulation observed at the protein level, there is an altered gene expression of ion channels, especially during the acute toxic phase. The Na þ /H þ exchanger isoform 1 (NHE-1) encoded by the gene SLC9A1 has in several studies been reported to play a role in events leading the cardiomyocyte hypertrophy (Jaballah et al., 2015; Mohamed et al., 2015; Nolly et al., 2015) . In our study we observed a clear upregulation of the SLC9A1 gene during the toxic exposure, potentially leading to , findings that may explain the impaired cardiac functionality. It has been reported that NHEs have important roles in the regulation of intracellular pH in cardiomyocytes, but also that elevated production of NHEs might contribute to cardiac pathology and that inhibition of NHE reduces apoptosis and attenuate induced cardiac injury (Karmazyn, 1998) .
One of the most interesting finding related to the HCM pathway is the effects on AMPK-related genes and proteins. The initial downregulation of genes encoding subunits of AMPK correlates to a recent study reporting that doxorubicin-induced apoptosis is caused by inhibition of AMPK activation (Gu et al., 2016) . The following upregulation of AMPK subunits seen in our data might be a defense mechanism by the cells, as several reports suggests a protective effect of AMPK activation on doxorubicin-induced cardiotoxicity (Kobashigawa et al., 2014; Liu et al., 2016) . In connection, the upregulated adenylate cyclase and GNAS seen in the dilated cardiomyopathy pathway, connected to an immunological response, most likely results in an increased production of cAMP and an additional positive effect on the AMPK activation.
The visualization of the ribosome pathway reveal an effect of doxorubicin on a number of ribosomal and mitochondrial ribosomal genes and proteins, most prominent during the acute toxic exposure. DE microRNAs overlap to a less extent with DE mRNAs and proteins compared with previous pathways, suggesting that the affected microRNAs has a lower impact on the ribosome function.
In conclusion, the analysis of the protein expression reported in this study adds value to ongoing mechanistic studies of doxorubicin-induced cardiotoxicity. The identified DE proteins support results from previous studies performed by us and others, and strengthens important findings of dysregulated genes and microRNAs and potential biomarkers for doxorubicin-induced cardiotoxicity. This study also demonstrates the utility of human pluripotent stem cell-derived cardiomyocytes for investigations of the responses to cardiotoxic stimuli and the possibilities to interrogate mechanistic events in detail. , 2018, Vol. 163, No. 1 
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